文献速递产科

足月妊娠阴道与口服米索前列醇引产比较:整群随机对照试验

Vaginal Compared With Oral Misoprostol Induction at Term: A Cluster Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2023-11-21

这项单中心整群随机试验将1322名足月孕妇分入阴道米索前列醇组(33个整群)、1224名分入口服米索前列醇组(37个整群)。两组首次引产阴道分娩率无显著差异(78.1% vs 77.2%,校正RR 1.01,95%CI 0.97-1.05)。阴道组伴胎心率变化的子宫过度收缩更少(3.5% vs 5.9%,校正RR 0.59,95%CI 0.40-0.87),分娩前需用缩宫素更少(68.8% vs 78.4%,校正RR 0.88,95%CI 0.84-0.92)。

要点

  • 足月引产时阴道与口服米索前列醇的首次引产阴道分娩率无显著差异(78.1% vs 77.2%,校正RR 1.01,95%CI 0.97-1.05)。
  • 阴道米索前列醇组伴胎心率变化的子宫过度收缩发生率低于口服组(3.5% vs 5.9%,校正RR 0.59,95%CI 0.40-0.87)。
  • 阴道米索前列醇组分娩前需用缩宫素的比例低于口服组(68.8% vs 78.4%,校正RR 0.88,95%CI 0.84-0.92)。

核心结论

  • 足月引产时阴道与口服米索前列醇方案相比未增加阴道分娩率,但减少了分娩前缩宫素的使用。

研究设计与样本

  • 单中心整群随机对照试验,按周随机分配引产方法,纳入孕龄37周及以上、宫颈扩张≤2 cm、胎膜完整且有分娩指征的孕妇。
  • 阴道米索前列醇组1322名(33个整群),方案为25微克每3小时一次、最多5剂;口服米索前列醇组1224名(37个整群),方案为100微克每4小时一次、最多2剂;随后均按标准化缩宫素方案。
  • 排除产前死胎、重大胎儿畸形、胎位异常、胎膜已破、胎儿状态不可靠或前列腺素禁忌者;结局按个体记录并校正整群效应,采用意向性治疗分析。
  • 研究时间为2021年5月24日至2022年9月19日;临床试验注册号ClinicalTrials.gov NCT04755218。

主要发现

  • 主要结局首次引产阴道分娩率:阴道米索前列醇组1032例(78.1%) vs 口服米索前列醇组945例(77.2%),校正RR 1.01,95%CI 0.97-1.05。
  • 伴胎心率变化的子宫过度收缩:阴道组3.5% vs 口服组5.9%,校正RR 0.59,95%CI 0.40-0.87。
  • 分娩前需用缩宫素:阴道组68.8% vs 口服组78.4%,校正RR 0.88,95%CI 0.84-0.92。
  • 两组分娩时间无差异;两组人口学特征及初始宫颈扩张无差异。

临床怎么用

  • 原文结论为足月引产时阴道与口服米索前列醇方案相比未增加阴道分娩率,但减少了分娩前缩宫素使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate efficacy in achieving vaginal delivery with a standardized vaginal compared with oral misoprostol regimen for labor induction at term. METHODS: In this single-center, cluster randomized trial, we randomized induction method by week among individuals with gestational age of 37 weeks or more, cervical dilation of 2 cm or less, intact membranes, and indication for delivery to either oral (100 micrograms every 4 hours for up to two doses), or vaginal (25 micrograms every 3 hours for up to five doses) misoprostol regimens, followed by a standardized oxytocin protocol. Individuals with an antepartum stillbirth, major fetal anomalies, malpresentation, ruptured membranes, nonreassuring fetal status, or contraindication to prostaglandin were excluded. The primary outcome was vaginal delivery at first induction attempt. Secondary outcomes included time to delivery, need for oxytocin, chorioamnionitis, and adverse maternal and neonatal outcomes. Outcomes were recorded at the individual level and adjusted for clustering, with analysis by intention to treat. RESULTS: Between May 24, 2021, to September 19, 2022, 1,322 women were randomized to vaginal misoprostol in 33 clusters and 1,224 to oral misoprostol in 37 clusters. Demographic characteristics or initial cervical dilation did not differ between groups. The primary outcome did not differ between induction regimens and occurred in 1,032 (78.1%) of the vaginal misoprostol arm and 945 (77.2%) of the oral misoprostol arm (adjusted relative risk [RR] 1.01, 95% CI, 0.97-1.05). Tachysystole with fetal heart rate changes occurred less frequently with vaginal compared with oral misoprostol (3.5% vs 5.9%, adjusted RR 0.59, 95% CI, 0.40-0.87). Time to delivery did not differ between groups. Oxytocin was less frequently required before delivery in the vaginal misoprostol group (68.8% vs 78.4%, adjusted RR 0.88, 95% CI, 0.84-0.92). CONCLUSION: Induction of labor with vaginal compared with oral misoprostol protocols did not increase the frequency of vaginal delivery at term but did reduce the need for oxytocin use before delivery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04755218.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Adhikari EH, McGuire J, Lo J, et al. Vaginal Compared With Oral Misoprostol Induction at Term: A Cluster Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 37989142. doi:10.1097/AOG.0000000000005464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。